{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"330"},{"groupId":"OG001","value":"329"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"343"}],"units":"Participants"}],"description":"TEAEs were AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.","groups":[{"description":"Participants received cemiplimab monotherapy","id":"OG000","title":"Cemiplimab"},{"description":"Participants received platinum-based doublet chemotherapy","id":"OG001","title":"Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety Analysis Set (SAF) included all randomized participants who received any study drug.","reportingStatus":"POSTED","timeFrame":"Up to 94 months","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}